Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia by Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Jon E. Arnason, Adam M. Boruchov, Caron A. Jacobson, David C. Fisher, Hari Miskin, Peter Sportelli, Jennifer R. Brown, Matthew S. Davids

Get full text

Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial by Geoffrey Shouse, Canping Chen, Alexandra Muir, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Alex F. Herrera, Olga Danilova, Carly Roleder, Lili Wang, Stephen E.F. Spurgeon, Adam S. Kittai, Lu Chen, Zheng Xia, Matthew S. Davids, Alexey V. Danilov

Get full text

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia by Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids

Get full text

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas by Alberto J. Arribas, Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas, Chiara Tarantelli, Roberta Bordone-Pittau, Luciano Cascione, Nicolas Munz, Luca Aresu, Jacopo Sgrignani, Andrea Rinaldi, Ivo Kwee, Davide Rossi, Andrea Cavalli, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Callum Sloss, Matthew S. Davids, Francesco Bertoni

Get full text

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia by James T. Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S. Choi, Stacey M. Fernandes, Philippe Armand, Amy C. Bessnow, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Reid W. Merryman, Oreofe O. Odejide, Erin M. Parry, David A. Qualls, Christine E. Ryan, Aswin Sekar, Jacob D. Soumerai, Jon Arnason, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Get full text

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL by Adam S. Kittai, Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Matthew S. Davids, Alexey V. Danilov, Wei Ding, Mark R. Dowling, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Paul J. Hampel, Carrie Ho, Steven R. Hwang, Prioty Islam, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Zulfa Omer, Sameer A. Parikh, Erin Parry, Kari G. Rabe, Philipp W. Raess, Manoj Rai, Lindsey Roeker, Joanna Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Hamish W. Scott, Mazyar Shadman, Geoffrey Shouse, Alan Skarbnik, Stephen Spurgeon, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, Max Yano, Jennifer A. Woyach

Get full text

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition by Antonino Glaviano, Hannah Si-Hui Lau, Lukas M. Carter, E. Hui Clarissa Lee, Hiu Yan Lam, Elena Okina, Donavan Jia Jie Tan, Wency Tan, Hui Li Ang, Daniela Carbone, Michelle Yi-Hui Yee, Muthu K. Shanmugam, Xiao Zi Huang, Gautam Sethi, Tuan Zea Tan, Lina H. K. Lim, Ruby Yun-Ju Huang, Hendrik Ungefroren, Elisa Giovannetti, Dean G. Tang, Tullia C. Bruno, Peng Luo, Mads Hald Andersen, Bin-Zhi Qian, Jun Ishihara, Derek C. Radisky, Salem Elias, Saurabh Yadav, Minah Kim, Caroline Robert, Patrizia Diana, Kurt A. Schalper, Tao Shi, Taha Merghoub, Simone Krebs, Anjali P. Kusumbe, Matthew S. Davids, Jennifer R. Brown, Alan Prem Kumar

Get full text